Hong Sang

Array ( [id] => 15664065 [patent_doc_number] => 10596240 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers [patent_app_type] => utility [patent_app_number] => 16/359165 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 33194 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16359165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227058 [patent_doc_number] => 20210353614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT [patent_app_type] => utility [patent_app_number] => 16/980058 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532364 [patent_doc_number] => 20220110973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => METHOD AND COMPOSITION FOR TREATING TUMORS [patent_app_type] => utility [patent_app_number] => 16/979102 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910365 [patent_doc_number] => 11873335 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Anti-folate receptor 1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/733541 [patent_app_country] => US [patent_app_date] => 2019-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 31 [patent_no_of_words] => 17474 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467823 [patent_doc_number] => 20190185554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => TARGETING CLPTM1L FOR TREATMENT AND PREVENTION OF CANCER [patent_app_type] => utility [patent_app_number] => 16/289023 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556110 [patent_doc_number] => 11312786 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Oncofetal antigen binding proteins and related compositions and methods [patent_app_type] => utility [patent_app_number] => 16/281440 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 62 [patent_no_of_words] => 58193 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16281440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17242024 [patent_doc_number] => 20210361767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => RESCUING CANCER PATIENTS FROM RESISTANCE TO TREATMENT WITH INHIBITORS OF PD-1/PD-L1 INTERACTIONS [patent_app_type] => utility [patent_app_number] => 16/970114 [patent_app_country] => US [patent_app_date] => 2019-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -107 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311607 [patent_doc_number] => 12037410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Methods and compositions for targeting Treg cells [patent_app_type] => utility [patent_app_number] => 16/969268 [patent_app_country] => US [patent_app_date] => 2019-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13122 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18201211 [patent_doc_number] => 11583582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response [patent_app_type] => utility [patent_app_number] => 16/274466 [patent_app_country] => US [patent_app_date] => 2019-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3300 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16274466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18948169 [patent_doc_number] => 11891450 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => Anti-CD47 agent-based treatment of CD20-positive cancer [patent_app_type] => utility [patent_app_number] => 16/272350 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 19 [patent_no_of_words] => 31193 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 203 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372533 [patent_doc_number] => 20190160179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => TREATMENT OF CANCER USING A COMBINATION OF IMMUNOMODULATION AND CHECK POINT INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/271153 [patent_app_country] => US [patent_app_date] => 2019-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16271153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649333 [patent_doc_number] => 20190231795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => METHODS FOR TREATING CANCER AND PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS [patent_app_type] => utility [patent_app_number] => 16/257831 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16257831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20911809 [patent_doc_number] => 12708644 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-18 [patent_title] => Dendritic cell vaccination sequential to chemotherapy [patent_app_type] => utility [patent_app_number] => 16/964847 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6416 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770904 [patent_doc_number] => 10981993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Anti-PD-1 monoclonal antibody and obtaining method therefor [patent_app_type] => utility [patent_app_number] => 16/251473 [patent_app_country] => US [patent_app_date] => 2019-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 17 [patent_no_of_words] => 7085 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16251473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16954925 [patent_doc_number] => 11058753 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Cancer vaccines [patent_app_type] => utility [patent_app_number] => 16/252239 [patent_app_country] => US [patent_app_date] => 2019-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33054 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16252239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15468633 [patent_doc_number] => 10550179 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => Compositions and methods for treating cancer with anti-mesothelin immunotherapy [patent_app_type] => utility [patent_app_number] => 16/252158 [patent_app_country] => US [patent_app_date] => 2019-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 26982 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16252158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14214027 [patent_doc_number] => 20190119398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => ANTI-SURVIVIN ANTIBODIES FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/233375 [patent_app_country] => US [patent_app_date] => 2018-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581403 [patent_doc_number] => 20190218310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => BISPECIFIC ANTIGEN BINDING CONSTRUCT [patent_app_type] => utility [patent_app_number] => 16/230326 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227387 [patent_doc_number] => 20190125866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/230134 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14497937 [patent_doc_number] => 20190192623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => SAPOSIN C-DOPS: A NOVEL ANTI-TUMOR AGENT [patent_app_type] => utility [patent_app_number] => 16/226468 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16226468 [rel_patent_id] =>[rel_patent_doc_number] =>)